Enhance MD vs Telos Rx: Semaglutide & Tirzepatide Pricing Compared
Looking for a direct cost and feature comparison between Enhance MD and Telos Rx? In short: Enhance MD advertises semaglutide from $49 and tirzepatide from $99 for the first month with flat-rate pricing at ongoing doses, while Telos Rx lists semaglutide as low as $99 and tirzepatide as low as $139 per month if a licensed provider approves you. This early verdict highlights price and pricing model as the key differences for many patients choosing between these two compounded GLP-1 platforms.
How Enhance MD vs Telos Rx differ on price structure and entry cost
Enhance MD emphasizes low introductory pricing: semaglutide from $49 first month and tirzepatide from $99 first month, then a flat-rate price that “stays the same at every dose” without escalation. Telos Rx presents semaglutide “as low as $99 per month” and tirzepatide “as low as $139 per month,” adding that pricing, eligibility, and state coverage may change and that the offer applies “if a licensed provider approves you.” Both note compounded medications are prescription-only and not FDA-approved.
Check Telos Rx pricing and eligibility
Five-point comparison table
| Criteria | Enhance MD | Telos Rx |
|---|---|---|
| Starting price | Semaglutide from $49 first month; tirzepatide from $99 first month | Semaglutide as low as $99 per month; tirzepatide as low as $139 per month |
| Ongoing pricing model | Flat-rate pricing: same price at every dose, no escalation | As low as pricing; terms may change and depend on approval |
| Compounds offered | Compounded semaglutide and compounded tirzepatide on one platform | Compounded semaglutide and compounded tirzepatide, clinician decides |
| Approval/eligibility | Treatment available only when a licensed clinician determines it is medically appropriate | Prescribed only after review by a US-licensed provider; pay $0 if not approved noted |
| Regulatory note | Compounded medications are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality | Compounded medications are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality |
Pricing transparency and dose escalation
Enhance MD markets a predictable billing approach: after the introductory month, an ongoing flat-rate price reportedly “stays the same at every dose” so there is no fee escalation during titration. The source explicitly positions this as a budgeting advantage. Telos Rx communicates “as low as” monthly rates and emphasizes that final price and renewal terms may change and depend on clinician approval and plan, so patients should confirm their total cost before enrollment.
Compare Enhance MD flat-rate details
Compound availability and clinician review
Both providers offer compounded semaglutide and tirzepatide rather than branded finished products. Enhance MD highlights availability of both compounds on one platform plus a reported treatment volume of more than 10,000 patients. Telos Rx frames molecule selection as clinician-driven, noting tirzepatide acts on GLP-1 and GIP while semaglutide acts on GLP-1, with a US-licensed provider deciding which is appropriate.
Service terms and enrollment notes
Enhance MD presents itself as a direct-pay clinician-directed platform with a stated low first-month price and flat-rate ongoing costs; it also notes that compounded medications are not FDA-approved. Telos Rx emphasizes clinician review, states “Pay $0 if not approved” in captured evidence, and warns that pricing, eligibility, pharmacy, state coverage and renewal terms may change. Both require a licensed clinician to determine medical appropriateness.
Review Telos Rx enrollment terms
What matters most: price entry, pricing model, and clinician approval
For a quick decision using the supplied facts: Enhance MD stands out on introductory entry cost and for promoting a flat-rate, no-escalation model. Telos Rx lists higher “as low as” monthly rates and emphasizes clinician approval and variable terms. Both use compounded medications that are not FDA-approved and require clinician review.
Choose Enhance MD if…
you prioritize the lowest first-month starting price for semaglutide (from $49) or tirzepatide (from $99) and want a flat-rate pricing model that the source says does not increase with higher doses.
Choose Telos Rx if…
you prefer a provider that lists “as low as” monthly pricing of $99 for semaglutide and $139 for tirzepatide and want to confirm eligibility and final price under a US-licensed provider’s review, noting Telos Rx advises verifying terms before enrollment.
Begin enrollment with Enhance MD
Primary keyword: Enhance MD vs Telos Rx